Psoriasis drug shows promise for kids in Real-World study

NCT ID NCT06142357

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 200 children aged 6 to 17 with moderate-to-severe plaque psoriasis who are taking secukinumab (Cosentyx). Researchers want to see how long patients stay on the drug, how well it controls their psoriasis, and how tolerable it is. The study collects data from the past and tracks patients going forward to get a real-world picture of the treatment's effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Secukinumab (Cosentyx)
What this could lead to: If successful, this study could confirm that secukinumab is a reliable long-term treatment option for children with moderate-to-severe plaque psoriasis.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It also only includes children already prescribed the drug, which may introduce bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE TO SEVERE PLAQUE PSORIASIS

Contacts and locations

Locations

Novartis Investigative Site

Chelyabinsk, 454048, Russia
Novartis Investigative Site

Grozny, 364022, Russia
Novartis Investigative Site

Izhevsk, 426009, Russia
Novartis Investigative Site

Kazan', 420012, Russia
Novartis Investigative Site

Kemerovo, 650025, Russia
Novartis Investigative Site

Moscow, 105007, Russia
Novartis Investigative Site

Moscow, 117513, Russia
Novartis Investigative Site

Moscow, 119296, Russia
Novartis Investigative Site

Moscow, 119435, Russia
Novartis Investigative Site

Mytishchi, 141009, Russia
Novartis Investigative Site

Nizhny Novgorod, 603950, Russia
Novartis Investigative Site

Rostov-on-Don, 344022, Russia
Novartis Investigative Site

Tolyatti, 445846, Russia
Novartis Investigative Site

Tula, 300053, Russia
Novartis Investigative Site

Ufa, 450000, Russia
Novartis Investigative Site

Yakutsk, 677000, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.